As AI tools flood open-source maintainers with low quality bug reports, OpenAI's new Patch the Planet initiative aims to filter out the noise and fix real threats.

Master ChatGPT Codex in 2026 with our comprehensive guide. Explore local automations, custom plugins, and memory features to ...

OpenAI is rolling out the full, limited-release version of GPT-5.5-Cyber—a specialized AI model that outperforms its ...

AI has taken the world by storm over the last few years, with millions of users writing prompts on platforms like ChatGPT to generate content, images, and yes videos. Still, some of these platforms ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Somerville company aims to ...

Generate:Biomedicines' anti-TSLP antibody GB-0895 is currently being evaluated in a pair of phase 3 studies for severe asthma. (Stock photo/Getty Images) Clinical-stage antibody company ...